睿知中国医院研究地图
候选清单

即将招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06548178,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:仅女性

    登记记录的入选字段

  2. Clinical stage at presentation (based on mammogram or breast MRI assessment): cT2 (>2cm, ≤5cm ), cN0, M0 as determined by the AJCC staging system, 8th edition (Hortobagyi et al 2017).

    入选标准第 3 条

  3. Evidence of post-menopausal status or negative serum pregnancy test for females of childbearing potential who are sexually active with a non-sterilized male partner. For women of childbearing potential, a negative result for serum pregnancy test (test must have a sensitivity of at least 25 mIU/mL) must be available at the screening visit and urine beta-human chorionic gonadotropin (β-HCG) pregnancy test prior to each administration of study treatment.

    入选标准第 9 条

    Woman of child-bearing potential defined as a woman physiologically capable of becoming pregnant, and not using highly effective methods of contraception during the study treatment and for 3 months after stopping the treatment.

    排除标准第 12 条

    Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline.

    排除标准第 27 条

  4. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1

    入选标准第 6 条

  5. Patients with a medical history of myocardial infarction (MI) within 6 months before randomisation, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV), Subjects with troponin levels above ULN at screening (as defined by the manufacturer), and without any myocardial related symptoms, should have a cardiologic consultation before enrolment to rule out MI.

    排除标准第 15 条

  6. Multiple primary malignancies within 3 years, with the exception of

    排除标准第 3 条

  7. Pregnant or breastfeeding female patients, or patients who are planning to become pregnant.

    排除标准第 39 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06548178,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Female, age ≥18 years at randomisation
  2. Participants with invasive, untreated Locally assessed HER2-positive (IHC 3+ or ISH+) according to ASCO-CAP guidelines (Wolff et al 2018), maximum 6 weeks before registration
  3. Clinical stage at presentation (based on mammogram or breast MRI assessment): cT2 (>2cm, ≤5cm ), cN0, M0 as determined by the AJCC staging system, 8th edition (Hortobagyi et al 2017).
  4. Written informed consent: Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol.
  5. LVEF ≥ 50% within 28 days before randomisation
  6. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1
  7. Adequate organ and bone marrow function within 14 days before randomisation as described: Platelet Count ≥ 100000/mm3; Haemoglobin ≥ 9.0 g/dL; Absolute neutrophil count ≥ 1500/mm3; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3×ULN; Total Bilirubin ≤ 1.5×ULN; Serum albumin ≥ 2.5 g/dL; CrCL ≥ 30 mL/min as determined by Cockcroft Gault (using actual body weight). International normalised ratio or Prothrombin time and either partial thromboplastin or activated partial thromboplastin time ≤ 1.5 × ULN. All parameters must be the most recent results available.
  8. Adequate treatment washout period before randomisation, defined as: Major Surgery ≥ 4 weeks; Radiation Therapy including palliative stereotactic radiation therapy to chest ≥ 4 weeks; Palliative stereotactic radiation therapy to other anatomic areas including whole brain radiation (see Exclusion Criteria 2) ≥ 2 weeks; Anti-Cancer chemotherapy [Immunotherapy (non-antibody based therapy)], retinoid therapy, hormonal therapy ≥ 3 weeks; Antibody based anti-cancer therapy ≥ 4 weeks; Targeted agents and small molecules ≥ 2 weeks or 5 half-lives, whichever is longer; Nitrosoureas or mitomycin C ≥ 6 weeks; TKIs approved for treatment of NSCLC ≥ 1 week; Chloroquine/Hydroxychloroquine ≥ 14 days; Cell-free and Concentrated Ascites Reinfusion Therapy (CART), peritoneal shunt or drainage of pleural effusion, ascites or pericardial effusion ≥2 weeks prior to screening assessment.
  9. Evidence of post-menopausal status or negative serum pregnancy test for females of childbearing potential who are sexually active with a non-sterilized male partner. For women of childbearing potential, a negative result for serum pregnancy test (test must have a sensitivity of at least 25 mIU/mL) must be available at the screening visit and urine beta-human chorionic gonadotropin (β-HCG) pregnancy test prior to each administration of study treatment.
  10. Female participants must not donate, or retrieve for their own use, ova from the time of enrolment and throughout the study treatment period, and for at least 7 months after the final study drug administration. They should refrain from breastfeeding throughout this time. Preservation of ova may be considered prior to enrollment in this study.

排除标准:Exclusion Criteria:

  1. Non-operable breast cancer including inflammatory breast cancer
  2. Any previous history of invasive breast cancer
  3. Multiple primary malignancies within 3 years, with the exception of
  4. adequately resected non-melanoma skin cancer
  5. curatively treated in-situ disease
  6. other solid tumors curatively treated
  7. Any evidence for existing metastatic disease (confirmed by CT Thorax/Abdomen, bone scan, or other methods according to clinical practice
  8. Previous or concurrent treatment with cytotoxic agents for any reason (except non-oncological reasons)
  9. Concurrent treatment with other experimental drugs and participation in another clinical trial with any investigational drug within 30 days prior to study entry
  10. Severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study/inadequate organ function
  11. Reasons indicating risk of poor compliance
  12. Woman of child-bearing potential defined as a woman physiologically capable of becoming pregnant, and not using highly effective methods of contraception during the study treatment and for 3 months after stopping the treatment.
  13. Use of oral (oestrogen and progesterone), transdermal, injected, or implanted hormonal methods of contraception as well as hormonal replacement therapy.
  14. Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results.
  15. Patients with a medical history of myocardial infarction (MI) within 6 months before randomisation, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV), Subjects with troponin levels above ULN at screening (as defined by the manufacturer), and without any myocardial related symptoms, should have a cardiologic consultation before enrolment to rule out MI.
  16. Corrected QT interval (QTcF) prolongation to > 470 msec (females) based on average of the screening triplicate12-lead ECG.
  17. History of QT prolongation associated with other medications that required discontinuation of that medication, or any current concomitant medication known to prolong the QT interval and cause TdP.
  18. Congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.
  19. History of (non-infectious) ILD / pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  20. Lung criteria:
  21. Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g. pulmonary emboli within three months of the study enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion etc.)
  22. Any autoimmune, connective tissue or inflammatory disorders (including Rheumatoid arthritis, Sjogren's and sarcoidosis) where there is documented, or a suspicion of pulmonary involvement at the time of screening. Full details of the disorder should be recorded in the eCRF for participants who are included in the study.
  23. Prior pneumonectomy (complete)
  24. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.
  25. Active primary immunodeficiency, known uncontrolled active human immunodeficiency virus (HIV) infection or active hepatitis B (hepatitis B virus surface antigen or hepatitis B virus core antibody positive, at screening) or C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Subjects should be tested for HIV prior to enrollment if required by local regulations or institutional review board (IRB)/ethics committee (EC).
  26. Receipt of live, attenuated vaccine (mRNA and replication deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first dose of trastuzumab deruxtecan or THP standard-of-care treatment.
  27. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline.
  28. Chemotherapy-induced neuropathy
  29. Fatigue
  30. Residual toxicities from prior IO treatment: Grade 1 or Grade 2 endocrinopathies which may include:
  31. Hypothyroidism/hyperthyroidism
  32. Type 1 diabetes
  33. Hyperglycaemia
  34. Adrenal insufficiency
  35. Adrenalitis
  36. Skin hypopigmentation (vitiligo)
  37. Known allergy or hypersensitivity to study treatment (T-DXd) or any of the study drug excipients.
  38. History of severe hypersensitivity reactions to other monoclonal antibodies.
  39. Pregnant or breastfeeding female patients, or patients who are planning to become pregnant.
  40. History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTCAE Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication or arrhythmias controlled by pacemakers may be permitted upon discussion with the Study Physician.

引自 ClinicalTrials.gov, NCT06548178, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06548178,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06548178